Cargando…

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment

BACKGROUND: Several studies have established a correlation between the VEGF–VEGFR2 axis and an immunosuppressive microenvironment; this immunosuppression can be overcome by anti-angiogenic reagents, such as ramucirumab (RAM). However, little is known about the immunological impact of anti-angiogenic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Yasuko, Togashi, Yosuke, Kotani, Daisuke, Kuwata, Takeshi, Sato, Eichi, Kawazoe, Akihito, Doi, Toshihiko, Wada, Hisashi, Nishikawa, Hiroyoshi, Shitara, Kohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186121/ https://www.ncbi.nlm.nih.gov/pubmed/30314524 http://dx.doi.org/10.1186/s40425-018-0403-1

Ejemplares similares

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
por: Ishii, Takahiro, et al.
Publicado: (2020)

Next-generation sequencing and biomarkers for gastric cancer: what is the future?
por: Kawazoe, Akihito, et al.
Publicado: (2019)

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
por: Yukami, Hiroki, et al.
Publicado: (2022)

The New Era of Immunotherapy in Gastric Cancer
por: Takei, Shogo, et al.
Publicado: (2022)

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
por: Isoyama, Sho, et al.
Publicado: (2021)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience
por: Kubota, Yohei, et al.
Publicado: (2022)

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
por: Fuchs, Charles S, et al.
Publicado: (2016)

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
por: Kawazoe, Akihito, et al.
Publicado: (2020)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens
por: Kashima, Yukie, et al.
Publicado: (2021)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

Gastric perforation related to concurrent use of nintedanib and ramucirumab
por: Takahashi, Saeko, et al.
Publicado: (2018)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Delayed Healing of Tooth Extraction Sockets with Ramucirumab Use
por: Iijima, Yosuke, et al.
Publicado: (2020)

Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
por: Arnold, D, et al.
Publicado: (2017)

Ramucirumab-related Oral Pyogenic Granuloma: A Report of Two Cases
por: Aragaki, Tadanobu, et al.
Publicado: (2021)

Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration
por: Morinaga, Takao, et al.
Publicado: (2022)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
por: Ibe, Tatsuya, et al.
Publicado: (2019)

Short-term safety of adjuvant chemoradiotherapy after local resection for patients with high-risk submucosal invasive rectal cancer: a single-arm, multicenter phase II trial
por: Noguchi, Masaaki, et al.
Publicado: (2021)

Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review
por: Fujii, Teruhiro, et al.
Publicado: (2019)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022)

Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report
por: Sasaki, Kimimasa, et al.
Publicado: (2021)

Gastrointestinal bleeding after aortic surgery: a case report
por: Shitara, Kohei, et al.
Publicado: (2009)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cc95hrq6v1v9f85u88p71ah4t3